Novartis AG (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 141   

Articles published

NVS 94.99 -0.28 (-0.29%)
price chart
Novartis's Signifor Closer To EU Approval
Novartis AG (ADR) (NVS) announced Friday that the European Medicines Agency (EMA) committee has given positive recommendations for its drug� Signifor LAR (pasireotide)� to the European Union (EU).
How To Make Money With Generics and Diagnostics [Novartis AG (ADR), Gilead ...
make-money The concept that generic and specialty pharmaceutical drugs cannot command pricing power and growth is a misunderstanding, according to Director and Senior Analyst Rohit Vanjani of Oppenheimer and Co.
Related articles »  
Novartis Posts Strong Third-Quarter Results; Cost-Cutting Efforts Pay Off
Novartis AG (ADR) (NVS) posted upbeat financial and operational results for the third quarter of its fiscal year (3QFY14) today before markets opened.
Related articles »  
Novartis Releases Positive Phase 3 Results For Psoriatic Arthritis Drug
Novartis AG (ADR) (NVS) today released top line results for two late-stage pivotal studies, which evaluated its novel drug secukinumab as a treatment for psoriatic arthritis (PsA).
Related articles »  
Novartis Announces Positive Phase-III Results For Secukinumab
Novartis AG (ADR) (NVS) announced today that its experimental drug AIN457 (Secukinumab) met its primary and secondary end points in two late-stage trials called MEASURE 1 and MEASURE-2.
Related articles »  
Technology Movers to Watch - Novartis AG (ADR)(NYSE:NVS), Quintiles ...
Novartis AG (ADR)(NYSE:NVS) patented prescription medicines in various therapeutic areas, including oncology; primary care and established medicines; specialty care, such as ophthalmology, neuroscience, integrated hospital care, and critical care; and ...
Related articles »  
Pharma Stock Updates - Pfizer Inc. (NYSE:PFE), Novartis AG (ADR) (NYSE:NVS ...
Novartis AG (ADR) (NYSE:NVS) said late on Wednesday that its experimental drug secukinumab worker better than a placebo in two pivotal Phase III studies on psoriatic arthritis, a long-lasting condition that causes joint pain and stiffness and which ...
Related articles »  
Biotech Stocks With Exciting Development Projects [Gilead Sciences, Inc ...
biotechnology Keith Markey, veteran analyst and science director of Griffin Securities, tells us the 2014 pipeline calendar positively glows with important milestones that could ignite portfolios.
Related articles »  
FDA Advisory Committee Votes In Favor Of Novartis' IL-17 Inhibitor
Novartis AG (ADR) (NVS) announced yesterday that the Dermatologic and Ophthalmic Drugs Advisory Committee to the FDA has unanimously recommended the use of Novartis' AIN457 in adults who are suffering from moderate-to-severe plaque psoriasis.
Related articles »  
Novartis Wins The Battle Over Bronchodilators Against GSK
Novartis AG ADR (NVS) reported yesterday that its once-daily Ultibro (Breezhaler) bronchodilator outperformed GlaxoSmithKline plc's (ADR) (GSK) twice-daily blockbuster Seretide (Accuhaler) bronchodilator in Phase-III trials.
Novartis (NVS) Presents Positive Data on Ultibro Breezhaler - Analyst Blog  NASDAQ
Related articles »